Trump 200% tariff: India’s cheap pills may still win
US President Donald Trump's proposed tariffs of up to 200% on generic medicines threaten India's pharmaceutical exports, but a report from the Global Trade Research Initiative (GTRI) suggests that India's cost advantage may keep many drugs competitive. Indian generics are priced seven to 10 times lower than branded alternatives, potentially allowing them to maintain market share despite the tariffs. The report emphasizes the need for India to diversify its pharmaceutical supply chain and reduce reliance on imported active pharmaceutical ingredients.